co nyse qqqq
lilli growth outlook improv cut cost
updat forecast estim apr
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research apr
estim apr
price data apr
rate updat apr
currenc amount express
valuat growth profit
methodolog valu compani
innov cultur strong financi commit
develop next gener drug set compani apart
peer fuel long-term growth follow steep
patent cliff lilli growth prospect improv
compani launch sever new blockbust patent loss
fade
lilli intern pipelin well posit mitig patent
loss next decad compani tend spend
sale financ develop effort new drug
much higher midteen industri averag robust
pipelin result lilli strong commit research
believ recent approv diabet drug trulic tradjenta
jardianc immunolog drug taltz olumi hold
highest sale potenti lilli new drug also sever lilli
late-stag cancer drug cyramza verzenio
develop blockbust addit clinic data hold
lilli strong entrench insulin product also help
compani deal patent loss unlik tradit drug
lilli insulin drug hard copi gener creat
barrier entri noninsulin produc larg
up-front invest need creat scale effici
lilli longer-act biosimilar insulin help compani
secur market share
compani take hard look bottom line
combin cost save expect top-lin growth lilli
aim reach oper margin believ
achiev pipelin success lilli expect increas
gross margin product initi greater
capac util may prove challeng
patent expir high-margin ciali alimta certain market
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
eli lilli pharmaceut compani focu neurosci
endocrinolog oncolog immunolog lilli key product includ
alimta cancer forteo osteoporosi jardianc trulic humalog
humulin diabet ciali erectil dysfunct also lilli
hold strong posit anim pharmaceut market
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqqq
valuat growth profit apr
rais fair valu estim per
share base stronger outlook margin improv
sever recent launch drug carri high margin
lift overal margin structur compani
overal compani look well-posit drive top-lin
growth project annual sale increas
next decad result new drug launch offset
patent loss particular outlook immunolog
drug taltz olumi look strong clinic data
support drug becom leader psoriasi
rheumatoid arthriti respect outsid immunolog
expect diabet drug jardianc trulic along
cancer drug cyramza becom increasingli import
driver cash flow particular jardianc look pois
hit peak sale project billion report
boehring ingelheim base strong cardiovascular
data anoth import point drive valuat cost
control increasingli think lilli abl meet
estim achiev oper margin
improv
outcom oper cost control depend new
revenu associ success recent launch
drug pipelin expect lilli reach goal
addit estim weight cost capit lilli
line compani peer group
larg base low volatil cash flow
divers inelast product portfolio rate lilli
uncertainti medium bit higher
pharma peer group partli high product
concentr risk surround compani pipelin
repres one fourth sale end
fair valu estim bull case
probabl bear case probabl project
fair valu estim rel base case
scenario analysi show moder varianc henc
medium uncertainti rate factor affect
scenario analysi includ degre success
brand drug pipelin magnitud market
pressur current market drug larg amount
valuat driven pipelin success new drug
launch clinic trial amplifi impact lilli
patent economi scale power distribut
drug carri strong price power enabl firm
gener return invest capit excess cost
capit patent give compani time
develop next gener drug gener
mean compani top drug repres moder
amount total sale largest drug humalog
repres total sale set manag
cash flow declin new product mitig gener
competit also lilli oper structur allow
cost-cut patent loss reduc margin
pressur lost high-margin drug sale overal lilli
establish product line creat enorm cash flow
need fund averag million develop
cost per new drug addit compani power
distribut network set compani strong partner
smaller drug compani lack lilli resourc lilli
entrench insulin franchis creat ad layer
competit advantag
competit seem mani year away due complex
gain gener approv insulin high cost
build need economi scale insulin product
given deceler patent loss strong pipelin
believ moat trend stabl next three
year compani key patent loss includ erectil
dysfunct drug ciali cardiovascular drug effient
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqqq
aggress price negoti rais bar futur
innov lilli sever headwind pipelin
hold sever biolog drug hold much stronger
competit advantag tradit small molecul
compani pipelin focus
innov treatment area unmet medic need
payer coverag price power remain strong
outsid pipelin compani strong insulin franchis
sale carri extra protect award
biolog economi scale need produc
rel lower-pr drug also compani
well-entrench anim health busi sale
oper matur stabl busi
experienc signific chang
potenti cancer drug alimta patent loss
next three year affect close total sale
compani strong pipelin combin stabl current
market drug lead annual revenu
growth period pipelin side
expect billion peak annual sale psoriasi
drug taltz rheumatoid arthriti drug olumi also
strong cardiovascular data lilli diabet drug
jardianc approv drive drug peak
annual sale billion
macro environ lilli sever headwind
make solid strateg move address challeng
neg side risk-sensit food drug
administr gener approv safe drug
drug high-ne area cancer also
managed-car organ pharmaci benefit
manag consolid past decad
use grow size demand lower drug price
reduc coverag less innov drug forc drug
firm push true innov reduc power
lilli distribut network govern
evalu compar effect program
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqqq
olilli launch new immunolog drug taltz
olumi offer better efficaci stronger
safeti profil tnf drug like set
obuoy sever recent acquisit lilli anim
health busi post stabl growth
olilli increas focu develop drug
unmet medic indic neurolog oncolog
strategi improv success rate
food drug administr drive strong price
olilli lag immuno-oncolog market may
creat competit headwind older cancer
osever lilli recent launch diabet drug
year behind competit launch
lack differenti could slow market share
oth alimta composit matter patent expir
could bring gener market
weaker patent expir
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqqq
equival begin period
total avail debt servic
oblig commit
total oblig commit
strong cash flow deriv stabl diversifi
product portfolio remain solid financi foot
expect compani debt/ebitda level fall
project level time
time also expect debt/capit ratio
fall close cash flow
accru year strong growth prospect
expect lilli need make major acquisit
drive growth nevertheless expect
acquisit augment growth compani
adjust free
gener
gener revolv adjust
commit
gener
manufactur brand-nam drugmak also
govern managed-car organ continu
consolid purchas power exert price
challeng liabil lawsuit patent risk
cancer drug alimta sale elev
patent strong composit matter patent
increas likelihood earlier-than-expect gener
competit also strong data novo new drug
like weigh growth prospect trulic
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqqq
view lilli stewardship rel standard
believ lilli use billion acquir imclon
like gener good return partnership
boehring ingelheim greatli improv strateg
outlook compani verdict still regard
lilli decis spend industry-lead amount
capit percentag sale research
develop pipelin look strong phase
data need determin return invest
lilli purchas price novarti anim healthcar
busi billion appear high increas
entrench anim health increas lilli
competit advantag well-posit industri
januari dave rick took helm
ceo follow smooth transit previou ceo
john lechleit retir rick bring strong experi
previous serv presid lilli biomedicin
group cover alzheim diseas urolog
immunolog musculoskelet diseas pain well
compani global market function rick
experi lilli date back join
compani busi develop associ dont
expect major chang transit senior
repres date owner name posit common share held report holder issuer
new jersey divis pension benefit
new york mellon corp
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqqq
buoy new drug expens control lilli post
strong result look under-valued apr
post strong first-quart result ahead
expect consensu dont
expect major shift fair valu estim base
minor out-performance continu see lilli
under-valued invest commun fulli
appreci compani new product launch
improv also
compani strong recent drug launch continu support
wide moat rate firm
top line total sale increas oper
driven sever new drug launch continu
drive sale next three year despit upcom
patent loss older drug product launch sinc
repres fourth total sale
grow close year year compani good
posit grow top line despit patent loss erectil
dysfunct drug ciali neurosci drug strattera
cardiovascular drug effient next two year
remain bullish recent launch immunolog drug taltz
despit inventori destock quarter lead
lower sale project continu expect
drug develop major blockbust base superior
efficaci better side effect profil versu older tnf
drug addit drug trulic continu post
strong growth expect growth
slow significantli next two year competitor
novo nordisk launch slightli better drug ozemp
dont expect trulic lose much market share well-
control diabet patient alreadi trulic expect
novo larg target new patient start ozemp
base larg potenti class lastli
expect immunolog drug olumi develop
blockbust recent food drug administr
panel concern cardiovascular side effect lead
slight decreas project drug
margin side lilli continu make progress toward
oper margin guidanc
expect firm achiev goal base
strong drug launch offer oper leverag
expect major recent launch drug carri
strong margin reach blockbust statu
complet overview lilli current market drug
pipelin pleas see healthcar observ steadi
pipelin off-set gener threat secur
conflict adcom vote creat headwind
lilli ra drug share under-valued apr
rheumatoid arthriti drug baricitinib
market olumi europ plan slightli
lower top-lin sale estim drug
expect impact margin neg impact
incyt per share fair valu estim immateri
impact lilli per share fair valu estim
narrow moat rate remain intact base
compani jakafi franchis rare blood cancer
unaffect vote
efficaci once-daili oral baricitinib
mg mg dose acknowledg nearli
unanim vote committe inadequ data rule
safeti imbal name thrombot event
placebo treatment arm ultim led
recommend mg dose reject
risk-benefit profil mg dose lower seriou infect
cancer rate seen baricitinib current
-approv jak inhibitor xeljanz could given
lilli drug edg competitor reach
 market opinion howev baricitinib
unclear safeti result regard thrombot event
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqqq
carri stronger efficaci safer side-effect profil
older market drug howev expect trulic
sale flatten novo nordisk launch ozemp
carri slightli stronger clinic data
bottom line lilli continu hold oper cost
flat even growth top line expect
trend continu next two year strong
oper leverag partli driven less demand
pipelin given strong line-up recent launch drug
well specialty-focus sale outreach
addit tax reform also add bottom-
line margin reduc core tax rate basi point
rel lilli initi guidanc basi point
lower project
lilli expect make strateg decis elanco
anim health busi believ
divestitur like major synergi
human anim health busi less need
lean group stabil lilli beyond heavi
patent loss year expect lilli split
complet overview lilli current market drug
pipelin pleas see healthcar observ steadi
pipelin off-set gener threat secur
flag xeljanz trial could muddi advantag
baricitinib member committe note
chanc seriou thrombot event
baricitinib-tr patient actual deviat
incid found gener rheumatoid arthriti
popul howev lack conclus safeti data
sway mani committe member vote toward
recommend mg dose
believ market larg bake sub-optimal
expect baricitinib follow complet respons
letter food drug administr fda
expect drug reach market believ
commerci opportun could constrain
approv label -- recommend dose mg versu
effect mg safeti warn fda
requir follow advisori committe recommend
introduc uncertainti gener fall line
guidanc believ incyt stock still look
under-valued increas interest compani
takeout target level
guidanc lead minor fve increas jan
eli lilli fourth-quart out-performance versu
consensu expect combin tax-rat guidanc
basi point expect like lead
minor fair valu estim increas view stock
slightli under-valued lilli strong new drug growth
reinforc convict firm wide moat rate
innov offset gener competit older
quarter new drug ad million
increment sale lilli total sale billion
oper offset gener pressur
expect posit trend continu next five
year area strength includ immunolog drug taltz
olumi diabet drug trulic jardianc
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqqq
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
co nyse qqqq
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
